4.4 Article

Myocardial iron overload assessment by T2*magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

期刊

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 93, 期 9, 页码 1385-1388

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.12759

关键词

cardiac iron; myelodysplastic syndromes; magnetic resonance imaging; T2*

向作者/读者索取更多资源

Only limited data are available regarding myocardial iron overload in adult patients with transfusion dependent acquired anemias. To address this topic using MRI T2* we studied 27 consecutive chronic transfusion dependent patients with acquired anemias: (22 myelodysplastic syndrome, 5 primary myelofibrosis). Cardiac MRI T2* values obtained ranged from 5.6 to 58.7 (median value 39.8) milliseconds. Of the 24 analyzable patients, cardiac T2* correlated with transfusion burden (p=0.0002). No patient who had received less than 290 mL/kg of packed red blood cells (101 units=20 grams of iron) had a pathological cardiac T2* value (< 20 ms). All patients who had received at least 24 PRBC units showed MRI T2* detectable hepatic iron (liver T2* value <= 6.3 ms). Only patients with severe hepatic iron overload (T2* <1.4 ms) showed cardiac T2* value indicative of dangerous myocardial iron deposition. Serum ferritin was not significantly correlated with cardiac T2* (p=0.24). Gradient echo T2* magnetic resonance imaging provides a rapid and reproducible method for detecting myocardial iron overload which developed after a heavy transfusion burden equal to or greater than 290 mL/kg of packed red blood cell units.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Cirino Botta, Antonella Bruzzese, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Antonino Neri, Nicola Di Renzo, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Massimo Gentile

Summary: The non-randomized comparison between KRd and EloRd therapies in relapsed/refractory multiple myeloma patients showed that KRd treatment led to a higher probability of achieving a CR+VGPR response, reduced progression or death risk, and had a greater effect on patients achieving CR+VGPR compared to those achieving < VGPR. The overall results suggest potential benefits of KRd therapy over EloRd in clinical practice.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Article Oncology

Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications

Claudio Fozza, Andrea Murtas, Giovanni Caocci, Giorgio La Nasa

Summary: Around one third of MDS patients have concomitant AD, but the burden of this association varies in different studies, possibly due to variations in selecting MDS patients and AD subtypes. The prognostic implications and therapeutic approaches for this patient subgroup are still debated.

LEUKEMIA RESEARCH (2022)

Article Oncology

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Fabio Efficace, Andrea Patriarca, Mario Luppi, Leonardo Potenza, Giovanni Caocci, Agostino Tafuri, Francesca Fazio, Claudio Cartoni, Maria Teresa Petrucci, Ida Carmosino, Riccardo Moia, Gloria Margiotta Casaluci, Paola Boggione, Elisabetta Colaci, Davide Giusti, Valeria Pioli, Francesco Sparano, Francesco Cottone, Paolo De Fabritiis, Nicolina Rita Ardu, Pasquale Niscola, Isabella Capodanno, Anna Paola Leporace, Sabrina Pelliccia, Elisabetta Lugli, Edoardo La Sala, Luigi Rigacci, Michelina Santopietro, Claudio Fozza, Sergio Siragusa, Massimo Breccia, Paola Fazi, Marco Vignetti

Summary: This study investigated physicians' perceptions of the usability and clinical utility of a digital health tool for electronic patient-reported outcome (ePRO) monitoring in patients with hematologic malignancies. The results showed that the majority of physicians found the tool easy to use and believed that ePRO data were useful for enhancing communication with their patients.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile

Summary: The present study developed two survival risk scores for relapsed/refractory multiple myeloma patients. The study found that several factors were associated with patients' survival and progression risks, and these risks could be classified using risk scores.

FRONTIERS IN ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Massimo Martino, Virginia Naso, Barbara Loteta, Filippo Antonio Canale, Marta Pugliese, Caterina Alati, Gerardo Musuraca, Davide Nappi, Anna Gaimari, Fabio Nicolini, Massimiliano Mazza, Sara Bravaccini, Daniele Derudas, Giovanni Martinelli, Claudio Cerchione

Summary: The approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T) has changed the treatment landscape for hematologic malignancies. However, there are still several challenges to be addressed, including the lack of initial responses and early relapse. New strategies are needed to increase the safety profile and shorten the manufacturing process of CAR-T cells therapy. The use of allogeneic CAR-T cells products generated from healthy donors has the potential to overcome these limitations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Oncology

Experts' consensus on the definition and management of high risk multiple myeloma

Chiara Marcon, Valentina Simeon, Paola Deias, Gabriele Facchin, Alessandro Corso, Daniele Derudas, Vittorio Montefusco, Massimo Offidani, Maria Teresa Petrucci, Renato Zambello, Raffaella Stocchi, Renato Fanin, Francesca Patriarca

Summary: This study conducted a survey to identify additional clinical and biological risk factors for high risk multiple myeloma (HRMM) and to evaluate if the management of multiple myeloma should change based on the risk category. The survey found a consensus regarding the inclusion of chromosome 1 abnormality, TP53 mutation or deletion, circulating plasma cells, and extramedullary plasmacytomas in the definition of HRMM. However, there was no consensus on the definition of double hit MM and the application of treatment strategies based on the risk category.

FRONTIERS IN ONCOLOGY (2023)

Article Medicine, General & Internal

Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy

Giovanni Caocci, Olga Mulas, Susanna Barella, Valeria Orecchia, Brunella Mola, Alessandro Costa, Fabio Efficace, Giorgio La Nasa

Summary: This study examined the long-term health-related quality of life (HRQoL) in adult patients with transfusion-dependent Beta-Thalassemia Major (b-TM) treated with splenectomy or medical therapy. The results showed that there was no significant difference in HRQoL between patients who underwent splenectomy and those who did not. Splenectomy reduced the frequency of blood transfusions but increased the risk of cardiovascular complications and diabetes.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Hematology

Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension

Olga Mulas, Brunella Mola, Alessandro Costa, Francesca Pittau, Daniela Mantovani, Samuele Dessi, Antonella Fronteddu, Giorgio La Nasa, Giovanni Caocci

Summary: This study found that hypertension is a significant risk factor for thrombotic-adverse events in patients with myeloproliferative neoplasms. The use of renin-angiotensin system inhibitors has a protective effect against these events.

ANNALS OF HEMATOLOGY (2023)

Article Medicine, General & Internal

Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey

Massimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, Daniela Cilloni, Monica Messina, Stefano Soddu, Fausto Castagnetti, Fabio Stagno, Paola Fazi, Alessandra Iurlo, Giovanni Caocci, Antonella Gozzini, Tamara Intermesoli, Mariella DAdda, Fabrizio Pane

Summary: Unmet needs exist in later lines of chronic myeloid leukemia (CML) treatment due to poor response and overall survival in resistant patients who switch to a second-generation TKI with similar action in the second line, as well as the increase in off-target toxicities and potential mutations. However, the recent approval of asciminib, a STAMP inhibitor, in the third line could change the treatment algorithm for this patient subset. A GIMEMA survey in Italy evaluated the current number of patients receiving third-line treatment, the current approach in later lines by Italian physicians, and the perceptions about the future role of asciminib.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study

Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Giulia Benevolo, Elena M. Elli, Francesco Cavazzini, Gianni Binotto, Alessia Tieghi, Mario Tiribelli, Florian H. Heidel, Massimiliano Bonifacio, Novella Pugliese, Giovanni Caocci, Monica Crugnola, Francesco Mendicino, Alessandra D'Addio, Simona Tomassetti, Bruno Martino, Nicola Polverelli, Sara Ceglie, Camilla Mazzoni, Rikard Mullai, Alessia Ripamonti, Bruno Garibaldi, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Giuseppe A. Palumbo, Alessandro Andriani, Michele Cavo, Roberto Latagliata, Valerio De Stefano

Summary: The prognostic relevance of complete response to hydroxyurea, predictors of response, and patients' triggers for switching to ruxolitinib in polycythemia vera are uncertain. Many PV patients receive underdosed hydroxyurea, leading to lower response and toxicity rates. Splenomegaly and other symptoms are the main drivers for early switch to ruxolitinib despite poor response to hydroxyurea.

CANCERS (2023)

Article Oncology

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis

Francesca Palandri, Giuseppe A. Palumbo, Massimiliano Bonifacio, Elena M. Elli, Mario Tiribelli, Giuseppe Auteri, Malgorzata M. Trawinska, Nicola Polverelli, Giulia Benevolo, Alessia Tieghi, Fabrizio Cavalca, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Marta Venturi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Filippo Branzanti, Nicola Vianelli, Michele Cavo, Florian Heidel, Alessandra Iurlo, Massimo Breccia

Summary: Predictors of early discontinuation of ruxolitinib therapy and death on therapy were investigated in patients with myelofibrosis. Low platelet and hemoglobin levels, primary myelofibrosis, no spleen response at 3 months, and low starting dose of ruxolitinib were associated with a higher probability of therapy failure. A predictive model was built to identify patients at higher risk of failure with ruxolitinib monotherapy, who should consider alternative frontline strategies.

CANCERS (2023)

Article Oncology

Clinical Rationale of Using Steerable Technologies for Radiofrequency Ablation Followed by Cavity Creation and Cement Augmentation in the Treatment of Painful Spinal Metastases

Claudio Pusceddu, Salvatore Marsico, Daniele Derudas, Nicola Ballicu, Luca Melis, Stefano Zedda, Carlo De Felice, Alessandro Calabrese, Domiziana Santucci, Eliodoro Faiella

Summary: This study evaluated the safety and efficacy of a steerable platform with an articulating radiofrequency ablation probe and targeted cavity creation in the treatment of painful spinal metastases. Sixteen patients underwent radiofrequency ablation and vertebral augmentation, resulting in significant improvement in pain and functional mobility. The combined treatment proved to be safe and effective.

CURRENT ONCOLOGY (2023)

Article Oncology

Percutaneous CT-Guided Microwave Ablation Combined with Pedicle Screw Fixation Followed by Vertebroplasty (MASFVA): Initial Experience of a Minimally Invasive Treatment of Vertebral Metastases with Extension to the Vertebral Pedicle

Claudio Pusceddu, Salvatore Marsico, Daniele Derudas, Nicola Ballicu, Luca Melis, Carlo de Felice, Alessandro Calabrese, Domiziana Santucci, Eliodoro Faiella

Summary: This study retrospectively evaluated the safety and efficacy of combined CT-guided percutaneous microwave ablation and pedicle screw fixation followed by vertebroplasty (MASFVA) for painful vertebral metastases with vertebral pedicle involvement. The results showed 100% technical success rate with no major complications. Pain scores and disability index significantly decreased, and patients were able to walk independently without neurological complications after one week. No new fractures or local recurrence occurred during follow-up.

CURRENT ONCOLOGY (2023)

Article Geriatrics & Gerontology

Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study

Fabio Efficace, Gianluca Gaidano, Maria Teresa Petrucci, Pasquale Niscola, Francesco Cottone, Katia Codeluppi, Elisabetta Antonioli, Agostino Tafuri, Alessandra Larocca, Leonardo Potenza, Claudio Fozza, Domenico Pastore, Gian Matteo Rigolin, Massimo Offidani, Alessandra Romano, Charalampia Kyriakou, Nicola Cascavilla, Alessandro Gozzetti, Daniele Derudas, Marco Vignetti, Michele Cavo

Summary: This study investigates the clinical utility of the International Myeloma Working Group frailty score in the management of relapsed or refractory multiple myeloma. The research examines the health-related quality of life profiles associated with different frailty groups and finds significant differences, particularly between fit and frail patients.

LANCET HEALTHY LONGEVITY (2022)

暂无数据